TY - JOUR
T1 - Characteristics and outcomes of acute pulmonary embolism among patients with polyvascular, single-vascular or no atherosclerotic disease
T2 - insights from RIETE
AU - Cardi, Silvia
AU - Barco, Stefano
AU - Wolf, Simon
AU - Demelo-Rodríguez, Pablo
AU - Pérez-Pinar, Montserrat
AU - Skride, Andris
AU - Tazi-Mezalek, Zoubida
AU - López-Sáez, Juan Bosco
AU - Marchena, Pablo Javier
AU - Monreal, Manuel
AU - RIETE Investigators
N1 - © 2025. The Author(s).
PY - 2025/6/30
Y1 - 2025/6/30
N2 - BACKGROUND: The role of atherosclerosis in pulmonary embolism (PE) prognosis remains uncertain. Our study assesses characteristics and outcomes of acute PE patients according to the presence and extent of atherosclerotic disease.METHODS: Using data from the RIETE registry, acute PE patients were classified into three groups based on personal history: (1) polyvascular atherosclerosis, (2) single vascular atherosclerosis, and (3) no symptomatic atherosclerosis. Primary outcomes included recurrent PE and venous thromboembolism (VTE), arterial events, major bleeding, and all-cause death. Hazard ratios (HR) and Kaplan-Meier curves for clinical outcomes were estimated using Cox regression models.RESULTS: Among 47,578 acute PE patients, 1,040 had polyvascular, 6,191 single-vascular, and 40,347 no atherosclerosis. During a median follow-up of 331 days, Adverse outcomes were more frequent in patients with atherosclerosis (vs. no atherosclerosis), rising with the number of affected vascular territories. Recurrent PE rates were 2.8, 1.6, and 1.2 per 100 patient-years in the polyvascular, single-vascular, and no atherosclerosis groups. Multivariable analysis showed a dose-dependent relationship between atherosclerosis and recurrent PE risk, with HRs of 3.2 (95% CI 1.7-5.9) and 1.6 (95% CI 1.1-2.3) for polyvascular and single-vascular disease (vs. no atherosclerosis). The risk of all-cause death followed a similar trend, with HRs of 1.3 (95% CI 1.1-1.6) and 1.2 (95% CI 1.1-1.4), respectively. Major bleeding appeared to be influenced by overall health status and antithrombotic therapy intensity.CONCLUSION: Atherosclerosis in acute PE patients may serve as a marker of disease severity and lead independently to adverse outcomes, highlighting the importance of cardiovascular risk stratification.
AB - BACKGROUND: The role of atherosclerosis in pulmonary embolism (PE) prognosis remains uncertain. Our study assesses characteristics and outcomes of acute PE patients according to the presence and extent of atherosclerotic disease.METHODS: Using data from the RIETE registry, acute PE patients were classified into three groups based on personal history: (1) polyvascular atherosclerosis, (2) single vascular atherosclerosis, and (3) no symptomatic atherosclerosis. Primary outcomes included recurrent PE and venous thromboembolism (VTE), arterial events, major bleeding, and all-cause death. Hazard ratios (HR) and Kaplan-Meier curves for clinical outcomes were estimated using Cox regression models.RESULTS: Among 47,578 acute PE patients, 1,040 had polyvascular, 6,191 single-vascular, and 40,347 no atherosclerosis. During a median follow-up of 331 days, Adverse outcomes were more frequent in patients with atherosclerosis (vs. no atherosclerosis), rising with the number of affected vascular territories. Recurrent PE rates were 2.8, 1.6, and 1.2 per 100 patient-years in the polyvascular, single-vascular, and no atherosclerosis groups. Multivariable analysis showed a dose-dependent relationship between atherosclerosis and recurrent PE risk, with HRs of 3.2 (95% CI 1.7-5.9) and 1.6 (95% CI 1.1-2.3) for polyvascular and single-vascular disease (vs. no atherosclerosis). The risk of all-cause death followed a similar trend, with HRs of 1.3 (95% CI 1.1-1.6) and 1.2 (95% CI 1.1-1.4), respectively. Major bleeding appeared to be influenced by overall health status and antithrombotic therapy intensity.CONCLUSION: Atherosclerosis in acute PE patients may serve as a marker of disease severity and lead independently to adverse outcomes, highlighting the importance of cardiovascular risk stratification.
KW - Atherosclerosis
KW - Cardiovascular disease
KW - Platelet aggregation inhibitors
KW - Pulmonary embolism
KW - Registries retrospective studies
KW - Venous thromboembolism
UR - https://pubmed.ncbi.nlm.nih.gov/40586901/
UR - https://www.mendeley.com/catalogue/d4caa510-4ce4-3eb0-af4b-ed337c26fd92/
UR - https://www.scopus.com/pages/publications/105013744726
U2 - 10.1007/s00392-025-02706-4
DO - 10.1007/s00392-025-02706-4
M3 - Article
C2 - 40586901
SN - 1861-0684
JO - Clinical Research in Cardiology
JF - Clinical Research in Cardiology
ER -